MASUI
IBRX icon

MIRAE ASSET SECURITIES (USA) INC.’s ImmunityBio IBRX Stock Holding History

MIRAE ASSET SECURITIES (USA) INC.’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-140,880
Closed -$361K – 226
2024
Q4 		$361K Buy
+140,880
New +$587K 0.01% 153
2024
Q3 		– Sell
-114,939
Closed -$726K – 183
2024
Q2 		$726K Buy
+114,939
New +$758K 0.03% 180

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MIRAE ASSET SECURITIES (USA) INC.'s IBRX Position: Q1 2025 in Review

MIRAE ASSET SECURITIES (USA) INC. sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 140,880 shares — an estimated $361K sold.

MIRAE ASSET SECURITIES (USA) INC. first reported a position in IBRX in Q2 2024 and held it in 2 quarters. The position peaked at $726K in Q2 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • MIRAE ASSET SECURITIES (USA) INC. reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • MIRAE ASSET SECURITIES (USA) INC. sold 140,880 ImmunityBio shares in Q1 2025, an estimated $361K.
  • MIRAE ASSET SECURITIES (USA) INC. first reported a position in ImmunityBio in Q2 2024 and held it in 2 quarters.
  • MIRAE ASSET SECURITIES (USA) INC.'s ImmunityBio position peaked at $726K in Q2 2024.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on MIRAE ASSET SECURITIES (USA) INC.'s 13F filing for Q1 2025, filed 15 May 2025.